Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Ironwood Pharmaceuticals (IRWD) over the last 15 years, with Q1 2025 value amounting to $161.0 million.

  • Ironwood Pharmaceuticals' Shares Outstanding (Weighted Average) rose 207.61% to $161.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $161.0 million, marking a year-over-year increase of 207.61%. This contributed to the annual value of $159.4 million for FY2020, which is 218.17% up from last year.
  • Ironwood Pharmaceuticals' Shares Outstanding (Weighted Average) amounted to $161.0 million in Q1 2025, which was up 207.61% from $159.0 million recorded in Q2 2024.
  • Ironwood Pharmaceuticals' 5-year Shares Outstanding (Weighted Average) high stood at $161.0 million for Q1 2025, and its period low was $155.4 million during Q2 2023.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $158.4 million (2024), whereas its average is $158.3 million.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first skyrocketed by 234.73% in 2024, then surged by 207.61% in 2025.
  • Ironwood Pharmaceuticals' Shares Outstanding (Weighted Average) (Quarter) stood at $155.4 million in 2023, then grew by 2.35% to $159.0 million in 2024, then rose by 1.23% to $161.0 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $161.0 million for Q1 2025, versus $159.0 million for Q2 2024 and $157.7 million for Q1 2024.